- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Stem Cells International
Volume 2012 (2012), Article ID 629230, 6 pages
The Potential of iPS Cells in Synucleinopathy Research
1Institute for Anatomy and Cell Biology, Ulm University, 89081 Ulm, Germany
2Department of Internal Medicine I, Ulm University, 89081 Ulm, Germany
Received 27 October 2011; Accepted 12 January 2012
Academic Editor: Mirella Dottori
Copyright © 2012 Leonhard Linta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
α-synuclein is a protein involved in the pathogenesis of several so-called synucleinopathies including Parkinson's disease. A variety of models have been so far assessed. Human induced pluripotent stem cells provide a patient- and disease-specific model for in vitro studies, pharmacotoxicological screens, and hope for future cell-based therapies. Initial experimental procedures include the harvest of patients’ material for the reprogramming process, the investigation of the patients genetic background in the cultured cells, and the evaluation of disease-relevant factors/proteins under various cell culture conditions.
1. α-Synuclein and Parkinson’s Disease
α-synuclein is a protein that is believed to interact with presynaptic vesicles and to be involved in the regulation of dopamine transport, secretion, and reuptake , possibly by interacting with the SNARE complex . In addition, it is believed to have additional nuclear and cytoplasmic functions. However it gained its prominence through its role in the pathology of Parkinson’s disease (PD) and several other neurodegenerative diseases summarized as synucleinopathies . -synuclein can form fibrils and -synuclein containing aggregates, so-called Lewy bodies and Lewy dendrites which are major characteristics of PD neuropathology. Their involvement in PD occurrence and neurodegeneration has not yet been finally unraveled. The discovery of synuclein overexpressing or point mutations in some PD patients, which have a higher tendency to form fibrils, additionally strengthened the belief that this protein has one of the central roles in PD . Several in vitro and in vivo models have therefore been established to study the formation of fibrils, Lewy Bodies, and the mechanism of neurodegeneration . Interestingly, the high tendency to form fibrils seems to be characteristic for the human protein. While mice overexpressing mouse -synuclein had no neural phenotype, mice overexpressing the human -synuclein suffered from neurodegeneration . This showed that although protein function and interactions as well as pathologic mechanisms could be partly analyzed in animals and cultured animal cells, all these findings have to be carefully checked in a human system which is as close to the real disease pathology as possible. In addition, the use of human cells could even reveal additional mechanistical findings that could not be mimicked in rodents.
2. Disease Models in Synucleopathies
Basically, disease modeling is performed in several branches. In brief, In vivo studies include primarily patient’s clinical features associated with disease morphology and progress [7, 8]. Clinical studies for PD include the evaluation of, for example, radiological changes (organ morphology, transmitter release/uptake, signs of degeneration such as plaques or metabolic dysfunction), symptom rating, disease course, or pharmacotoxicological trials. Secondly, genetic investigations searching for disease relevant gene abberations and familiar cosegregation are of great value for the understanding and treatment of such degenerative syndromes. Additionally, in vivo modeling includes several animal models starting from lower animals such as the worm C. elegans, the fly D. melanogaster or the Zebrafish D. rerio [9, 10]. These kinds of animal models not only provide systematic insights into genetic disease background but also help to elucidate pathways in pathogenesis. Apart from that, they allow a relatively easy to handle model at low costs. Still, diseases like PD also involve studies using higher animals up to models mimicking the human organism, namely, monkeys and apes. Certainly, most higher animal models consist of mice models in various compositions . These mice can nowadays be generated relatively easy with valuable features such as genetic knock down or even organ specific and/or in an inducible manner. These models are utilized for a variety of studies. Mouse models in general stand for investigations of, for example, the pathomechanisms, disease progression, gene function, or pharmacotoxicological evaluations. On the other hand, in vitro studies often make use of cellular setups. Of high interest for PD studies are cell cultures consisting of dopaminergic neurons from different sources. Until recently, most of these cell models were harvested from rodents or other animals. Investigations on these models carry the advantage of broad access to detailed cellular mechanisms. Genetic modulation of single cells additionally provide insights into cellular processes such as differentiation, migration, and function or degenerating processes such as apoptosis or necrosis. Especially, stem cells are used for studies of differentiation and maturation. In PD several different sources and types of stem cells are used. The following exemplary differences exist: (i) pluripotent embryonic stem (ES) cells are a good source for dopaminergic neurons and may be used for future cell therapeutic approaches and as platforms for pharmacotoxicological assays. Still, they inherit ethical and legal prohibitions and harbor certain dangers such as teratoma formation in vivo. (ii) Neural stem cells (adult stem cells) provide a source for even autologous dopaminergic neurons and can be used for patient-specific and disease-specific pathogenic investigations [11–15]. Nevertheless, these cells are extremely difficult to harvest, and this is only possible by harmful surgical intervention. Additionally, (up to now) these cells cannot be passaged over a long time and lose their potential to generate dopaminergic neurons over time. (iii) Mesenchymal stem cells from the bone marrow are thought to be amongst the most easy to harvest individual stem cell sources. These cells are also thought to be a certain source for dopaminergic neurons and provide a good hope for future cell-based therapies for a variety of neurodegenerative disorders . But, the efficiency of dopaminergic differentiation is very low and research is still far away from a cell-based therapy.
3. Induced Pluripotent Stem Cells as a Disease Model
Studying neurodegenerative diseases in human cells is of course a difficult task. Since the affected cells cannot be propagated in culture and the supply of primary material is very limited, they cannot be widely used as a model system. As depicted in the last paragraph the use of ES cells and the subsequent differentiation into neural stem cells and neurons could partially circumvent this barrier. However their use is discussed very controversially in several countries due to ethical concerns. This issue has been resolved by the discovery of induced pluripotent stem cells (iPS cells). iPS cells are produced from somatic cells like fibroblasts or keratinocytes and can be reprogrammed by the forced overexpression of certain transcription factors (known as the Yamanaka factors Oct4, Sox2, Klf4, c-Myc (OSKM)) into a state that strongly resembles embryonic stem cells . These cells can subsequently be subjected to differentiation into virtually all cells of the organism  and of course to neural differentiation (as depicted in Section 4 in more detail) (Figure 1(a)), especially into dopaminergic neurons which are most affected by PD . This method could prove even more valuable by the use of cells from PD patients with α-synuclein mutations to evaluate and compare their iPS cell-derived neurons with healthy ones. By these means it is possible to verify findings from animal cell culture systems and other in vitro assays in human cells very similar or even identical to the ones which are actually affected in PD patients. Therefore it is of importance to establish a variety of iPS cell lines from different donors with α-synuclein-related diseases.
4. Generation and Differentiation of Patient-Specific iPS Cells
The first question when reprogramming somatic cells into iPS cells is that of the cell type being reprogrammed. Traditionally, most groups used fibroblasts from punch biopsies since they are relatively easy to get and to propagate. However, when planning to generate patient-specific cell lines one has to consider that the acceptance to perform a punch biopsy is not very high since it is still an invasive and painful process. Therefore we favor the use of keratinocytes from plucked scalp hair as a starting cell source (Figure 1(b)). These cells can be obtained by noninvasive means and, in addition, have a much higher reprogramming efficiency compared to skin fibroblasts [18, 20]. Recent findings indicating that redifferentiating iPS cells favor cell types close to their origin before reprogramming reinforce the benefits of keratinocytes as starting cells since they are of ectodermal origin and closer related to neurons than fibroblasts .
The delivery of the four reprogramming factors Oct4, Sox2, Klf4 and c-Myc is preferably done via lentiviral transfection of a polycistronic and excisable construct. This system still harbors the highest efficiencies [22, 23]. Although there were several other methods described, including transient transfection or protein transduction [24, 25], these have very low efficiencies and are not well usable for the generation of patient-specific cell lines. The transfection of modified RNAs was described as very efficient for reprogramming but has still to be evaluated on a broader basis . Lentiviral transfection of course has the negative effect of random DNA integration into the genome. This can partially be diminished by using cre-excisable lentiviral constructs. However, in order to minimize side effects caused by the integration as well as the variances between different lines it is important to evaluate a certain number of lines, preferably from different donors.
When producing patient-specific iPS cells it is important to have high reprogramming efficiencies, since the patient material is limited. Therefore the use of high-quality cultures of the reprogrammed cells as well as the feeder cells used in the reprogramming process is crucial. In addition several selection methods have been described to ease the isolation of true iPS cells [27, 28]. The arising iPS cells have to be thoroughly characterized to ensure their true iPS cell identity (Figure 1(c)).
The differentiation of iPS cells into neurons has already been extensively studied with ES cells [29, 30]. Available protocols, although greatly varying in detail, share some general steps. Typically, differentiation of iPS cells is started by withdrawal of FGF2. In suspension culture this is used to form embryoid bodies containing precursor cells of all lineages. The differentiation into the ectodermal and neuroectodermal lineage can, however, be highly enhanced by addition of the BMP antagonist Noggin (as well as the small molecule dorsomorphin) and even more in combination with SB431542, a TGFβ pathway inhibitor [31, 32]. Together these two substances can induce strong neural differentiation even under adherent conditions and in lines with a low neural differentiation potential. Under adherent conditions cells start to form neural rosettes (Figure 1(d)). They consist of PAX6 or Nestin-positive neural stem cells (NSCs) and mimic the development of the neural tube in vitro. To exclude undifferentiated cells or cells differentiating into a different fate the inner regions of the neural rosettes can be mechanically or enzymatically detached. This ensures a high purity and a similar differentiation stage of the NSCs. NSCs can be cultured under adherent conditions or in suspension as neurospheres (Figure 1(e)). However, it is not clear for how long these cells can be cultured without a reduction or change in their differentiation potential. Different culture conditions for NSCs and thereafter of the arising neurons have been reported to favor the generation of certain neuronal subtypes, like glutamatergic neurons, dopaminergic neurons, or motor neurons (Figure 1(f)) [30, 33]. To induce final differentiation cells are treated with a mixture neurotrophic factors like the brain-derived or the glial-derived neurotrophic factor (BDNF and GDNF) as well as region-specific morphogens like Sonic hedgehog. High reproducibility in cell survival, culture quality and synapse formation has been reported for cocultures with glial cells . These could be of mouse or human origin but also generated themselves from patient-specific iPS cells . Of course this could be of relevance especially for diseases where glial cells cause or contribute to the pathologic effects.
5. Perspectives in iPS Cell-Based Synucleinopathy Research
The aim of upcoming iPS cell-based studies would be to study the morphology and electrophysiological behavior of synucleinopathy-derived neurons and compare them with healthy cells. Since synuclein is especially involved in the synaptic compartment, alterations there would be of great interest . It was already shown that iPS cell-derived human neurons express synuclein . The first synuclein-related patient iPS cell line-derived neurons with a triplication of the synuclein (SNCA) gene show a higher amount of synuclein protein compared to healthy control cells . In addition to the already published relatively young neurons, we could show α-synuclein in immunostainings of mature iPS cell-derived neurons with a nuclear as well as vesicular staining pattern (Figure 2(a)). They also express the gene at a higher rate compared to iPS cells or NSCs (Figure 2(b)). Interestingly, the gene LRRK2 (leucine-rich repeat kinase 2) is also upregulated in differentiated neurons (Figure 2(c)). This PD-associated gene was described to enhance the ability of α-synuclein to form aggregates . Neurons derived from patient iPS cells with a LRRK2 mutation show enhanced stress sensitivity and an elevated synuclein levels . In a subcellular fractionation α-synuclein is present in the nuclear fraction (P1) but mainly in the P2 fraction containing membrane associated proteins and the synaptic compartment (Figure 2(d)). Another very intriguing study would be to evaluate ageing in these iPS cell-derived neurons. For this they have to be kept in culture for prolonged periods of time and/or additionally stressed to provoke the formation of plaque-like structures in vitro. This would be a very powerful tool since it then would recapitulate the neuronal changes observed in PD patients. If cultured cells can be reliably provoked to form synuclein aggregates and plaques they also would be an ideal readout system for pharmaceutical research and evaluation of potential PD drugs. Since solely human α-synuclein and its mutated forms seem to have this high tendency to form plaques the use of iPS cell-derived human neurons can be crucial to evaluate the exact pathomechanisms involved in formation of synucleinopathies. The final step would be to recapitulate the observed phenotypes of the patient-derived cells in healthy cells where the genes of interest are artificially modified. This method has already been demonstrated with α-synuclein point mutations . The additional use of such isogenic controls with single alterations is important to finally prove the monogenic disease potential of genes like α-synuclein or LRRK2 and rule out additional but yet unknown mutations.
Conflict of Interests
The authors declare no potential conflicts of interest.
- A. Sidhu, C. Wersinger, and P. Vernier, “Does α-synuclein modulate dopaminergic synaptic content and tone at the synapse?” FASEB Journal, vol. 18, no. 6, pp. 637–647, 2004.
- J. Burré, M. Sharma, T. Tsetsenis, V. Buchman, M. R. Etherton, and T. C. Südhof, “α-synuclein promotes SNARE-complex assembly in vivo and in vitro,” Science, vol. 329, no. 5999, pp. 1663–1667, 2010.
- M. Goedert, “Alpha-synuclein and neurodegenerative diseases,” Nature Reviews Neuroscience, vol. 2, no. 7, pp. 492–501, 2001.
- K. A. Conway, J. D. Harper, and P. T. Lansbury, “Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease,” Nature Medicine, vol. 4, no. 11, pp. 1318–1320, 1998.
- M. F. Chesselet, “In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?” Experimental Neurology, vol. 209, no. 1, pp. 22–27, 2008.
- S. Chandra, G. Gallardo, R. Fernández-Chacón, O. M. Schlüter, and T. C. Südhof, “α-synuclein cooperates with CSPα in preventing neurodegeneration,” Cell, vol. 123, no. 3, pp. 383–396, 2005.
- H. Braak, D. R. Thal, and K. Del Tredici, “Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson's disease cases,” Journal of Neural Transmission, vol. 118, no. 5, pp. 809–819, 2011.
- N. K. Focke, G. Helms, P. M. Pantel et al., “Differentiation of typical and atypical Parkinson syndromes by quantitative MR imaging,” American Journal of Neuroradiology, vol. 32, no. 11, pp. 2087–2092, 2011.
- Z. Liu, S. Hamamichi, B. D. Lee et al., “Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models,” Human Molecular Genetics, vol. 20, no. 20, pp. 3933–3942, 2011.
- I. S. Pienaar, J. Götz, and M. B. Feany, “Parkinson's disease: insights from non-traditional model organisms,” Progress in Neurobiology, vol. 92, no. 4, pp. 558–571, 2010.
- A. Hermann, M. Maisel, F. Wegner et al., “Multipotent neural stem cells from the adult tegmentum with dopaminergic potential develop essential properties of functional neurons,” Stem Cells, vol. 24, no. 4, pp. 949–964, 2006.
- S. Liebau, B. Vaida, C. Proepper et al., “Formation of cellular projections in neural progenitor cells depends on SK3 channel activity,” Journal of Neurochemistry, vol. 101, no. 5, pp. 1338–1350, 2007.
- S. Liebau, B. Vaida, A. Storch, and T. M. Boeckers, “Maturation of synaptic contacts in differentiating neural stem cells,” Stem Cells, vol. 25, no. 7, pp. 1720–1729, 2007.
- S. Liebau, C. Pröpper, T. Böckers et al., “Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation,” Journal of Neurochemistry, vol. 99, no. 2, pp. 426–437, 2006.
- A. Hermann, M. Maisel, S. Liebau et al., “Mesodermal cell types induce neurogenesis from adult human hippocampal progenitor cells,” Journal of Neurochemistry, vol. 98, no. 2, pp. 629–640, 2006.
- K. A. Trzaska and P. Rameshwar, “Dopaminergic neuronal differentiation protocol for human mesenchymal stem cells,” Methods in Molecular Biology, vol. 698, pp. 295–303, 2011.
- K. Takahashi, K. Tanabe, M. Ohnuki et al., “Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors,” Cell, vol. 131, no. 5, pp. 861–872, 2007.
- M. Müller, S. Stockmann, D. Malan, et al., “Ca2+-activated K+ -Channels -new tools to induce cardiac commitment from pluripotent stem cells in mice and men,” Stem Cell Reviews and Reports. In press.
- A. Swistowski, J. Peng, Q. Liu et al., “Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions,” Stem Cells, vol. 28, no. 10, pp. 1893–1904, 2010.
- T. Aasen, A. Raya, M. J. Barrero et al., “Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes,” Nature Biotechnology, vol. 26, no. 11, pp. 1276–1284, 2008.
- O. Bar-Nur, H. A. Russ, S. Efrat, and N. Benvenisty, “Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells,” Cell Stem Cell, vol. 9, no. 1, pp. 17–23, 2011.
- C. A. Sommer, A. G. Sommer, T. A. Longmire et al., “Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector,” Stem Cells, vol. 28, no. 1, pp. 64–74, 2010.
- C. A. Sommer, M. Stadtfeld, G. J. Murphy, K. Hochedlinger, D. N. Kotton, and G. Mostoslavsky, “Induced pluripotent stem cell generation using a single lentiviral stem cell cassette,” Stem Cells, vol. 27, no. 3, pp. 543–549, 2009.
- Y. Junying, H. Kejin, S. O. Kim et al., “Human induced pluripotent stem cells free of vector and transgene sequences,” Science, vol. 324, no. 5928, pp. 797–801, 2009.
- H. Zhou, S. Wu, J. Y. Joo et al., “Generation of induced pluripotent stem cells using recombinant proteins,” Cell Stem Cell, vol. 4, no. 5, pp. 381–384, 2009.
- L. Warren, P. D. Manos, T. Ahfeldt et al., “Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA,” Cell Stem Cell, vol. 7, no. 5, pp. 618–630, 2010.
- A. Hotta, A. Y. L. Cheung, N. Farra et al., “Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency,” Nature Methods, vol. 6, no. 5, pp. 370–376, 2009.
- B. Di Stefano, S. M. Maffioletti, B. Gentner et al., “A microRNA-based system for selecting and maintaining the pluripotent state in human induced pluripotent stem cells,” Stem Cells, vol. 29, no. 11, pp. 1684–1695, 2011.
- S. C. Zhang, M. Wernig, I. D. Duncan, O. Brüstle, and J. A. Thomson, “In vitro differentiation of transplantable neural precursors from human embryonic stem cells,” Nature Biotechnology, vol. 19, no. 12, pp. 1129–1133, 2001.
- P. Koch, T. Opitz, J. A. Steinbeck, J. Ladewig, and O. Brüstle, “A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 9, pp. 3225–3230, 2009.
- A. Morizane, D. Doi, T. Kikuchi, K. Nishimura, and J. Takahashi, “Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells,” Journal of Neuroscience Research, vol. 89, no. 2, pp. 117–126, 2011.
- S. M. Chambers, C. A. Fasano, E. P. Papapetrou, M. Tomishima, M. Sadelain, and L. Studer, “Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling,” Nature Biotechnology, vol. 27, no. 3, pp. 275–280, 2009.
- M. Stockmann, L. Linta, K. J. Föhr, et al., “Developmental and functional nature of human iPSC derived motoneurons,” Stem Cell Reviews and Reports. In press.
- K. J. Brennand, A. Simone, J. Jou et al., “Modelling schizophrenia using human induced pluripotent stem cells,” Nature, vol. 473, no. 7346, pp. 221–225, 2011.
- R. Krencik, J. P. Weick, Y. Liu, Z.-J. Zhang, and S.-C. Zhang, “Specification of transplantable astroglial subtypes from human pluripotent stem cells,” Nature Biotechnology, vol. 29, no. 6, pp. 528–534, 2011.
- J. R. Mazzulli, Y.-H. Xu, Y. Sun et al., “Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies,” Cell, vol. 146, no. 1, pp. 37–52, 2011.
- M. J. Devine, M. Ryten, P. Vodicka et al., “Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus,” Nature Communications, vol. 2, no. 1, p. 440, 2011.
- K. Kondo, S. Obitsu, and R. Teshima, “α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells,” Biological and Pharmaceutical Bulletin, vol. 34, no. 7, pp. 1078–1083, 2011.
- H. N. Nguyen, B. Byers, B. Cord et al., “LRRK2 mutant iPSC-derived da neurons demonstrate increased susceptibility to oxidative stress,” Cell Stem Cell, vol. 8, no. 3, pp. 267–280, 2011.
- F. Soldner, J. Laganière, A. W. Cheng et al., “Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations,” Cell, vol. 146, no. 2, pp. 318–331, 2011.